Curaleaf Holdings (CURLF) Cash from Investing Activities (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Cash from Investing Activities of -$26.0 million for Q4 2024, down 26.31% year-over-year from -$35.3 million in Q1 2024, and up 6.25% quarter-over-quarter from -$27.7 million in Q3 2024.
Curaleaf Holdings (CURLF) Cash from Investing Activities (2019 - 2024) Analysis & Trends
Curaleaf Holdings' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$26.0 million for Q4 2024.
- In Q4 2024, Cash from Investing Activities fell 26.31% year-over-year to -$26.0 million; the TTM figure through Dec 2024 stood at -$93.8 million (down 19.24% YoY), while the FY2025 annual figure was -$70.3 million, up 25.03% from the prior year.
- Cash from Investing Activities for Q4 2024 stood at -$26.0 million, up from -$27.7 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $26.7 billion in Q2 2023, with the low at -$26.7 billion in Q1 2023.
- The 5-year median for Cash from Investing Activities is -$29.6 million (2021), against an average of -$31.1 million.
- Peak annual rise in Cash from Investing Activities reached 97.08% in 2021, while the deepest fall reached 88207.28% in 2021.
- Curaleaf Holdings' Cash from Investing Activities stood at -$26.7 million in 2020, then sank by 211.2% to -$83.1 million in 2021, then jumped by 54.1% to -$38.1 million in 2022, then surged by 46.06% to -$20.6 million in 2023, then fell by 26.31% to -$26.0 million in 2024.
- Business Quant data shows CURLF's Cash from Investing Activities at -$26.0 million in Q4 2024, -$27.7 million in Q3 2024, and $17.5 billion in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Curaleaf Holdings | 2.48 Bn | 2.38 Bn | 169.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -25.99 Mn |
| Dec 31, 2024 | -25.99 Mn |
| Sep 30, 2024 | -27.72 Mn |
| Sep 30, 2024 | -27.72 Mn |
| Jun 30, 2024 | 17.51 Bn |
| Jun 30, 2024 | 17.51 Bn |
| Mar 31, 2024 | -17.55 Bn |
| Mar 31, 2024 | -17.55 Bn |
| Dec 31, 2023 | -20.58 Mn |
| Dec 31, 2023 | -20.58 Mn |
| Sep 30, 2023 | -20.17 Mn |
| Sep 30, 2023 | -20.17 Mn |
| Jun 30, 2023 | 26.69 Bn |
| Jun 30, 2023 | 26.69 Bn |
| Mar 31, 2023 | -26.73 Bn |
| Mar 31, 2023 | -26.73 Bn |
| Dec 31, 2022 | -38.15 Mn |
| Dec 31, 2022 | -38.15 Mn |
| Sep 30, 2022 | -42.11 Mn |
| Sep 30, 2022 | -42.11 Mn |